2 December 2022 - Application includes data from key Phase 3 trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy outcomes.
GSK today announced that the EMA validated the marketing authorisation application for momelotinib, a potential new oral treatment for myelofibrosis.